185 related articles for article (PubMed ID: 25512056)
1. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.
Clement SC; van Rijn RR; van Eck-Smit BL; van Trotsenburg AS; Caron HN; Tytgat GA; van Santen HM
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):706-15. PubMed ID: 25512056
[TBL] [Abstract][Full Text] [Related]
2. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.
van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
Cancer; 2002 Apr; 94(7):2081-9. PubMed ID: 11932913
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.
Clement SC; van Eck-Smit BL; van Trotsenburg AS; Kremer LC; Tytgat GA; van Santen HM
Pediatr Blood Cancer; 2013 Nov; 60(11):1833-8. PubMed ID: 23832530
[TBL] [Abstract][Full Text] [Related]
4. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.
van Santen HM; de Kraker J; van Eck BL; de Vijlder JJ; Vulsma T
Cancer; 2003 Jul; 98(2):389-96. PubMed ID: 12872361
[TBL] [Abstract][Full Text] [Related]
5. Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.
van Santen HM; Tytgat GA; van de Wetering MD; van Eck-Smit BL; Hopman SM; van der Steeg AF; Nieveen van Dijkum EJ; van Trotsenburg AS
Thyroid; 2012 Jun; 22(6):643-6. PubMed ID: 22524499
[TBL] [Abstract][Full Text] [Related]
6. [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma].
Garrido Magaña E; Silva Estrada JA; Nishimura Meguro E; Rivera Hernández AJ; Zurita Cruz JN
Rev Chil Pediatr; 2020 Jun; 91(3):379-384. PubMed ID: 32730518
[TBL] [Abstract][Full Text] [Related]
7. Endocrine late effects from multi-modality treatment of neuroblastoma.
van Santen HM; de Kraker J; Vulsma T
Eur J Cancer; 2005 Aug; 41(12):1767-74. PubMed ID: 16039114
[TBL] [Abstract][Full Text] [Related]
8. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
Garaventa A; Gambini C; Villavecchia G; Di Cataldo A; Bertolazzi L; Pizzitola MR; De Bernardi B; Haupt R
Cancer; 2003 Mar; 97(5):1332-8. PubMed ID: 12599242
[TBL] [Abstract][Full Text] [Related]
9. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
[TBL] [Abstract][Full Text] [Related]
10. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
[TBL] [Abstract][Full Text] [Related]
11. Thyroid function after diagnostic
Clement SC; Tytgat GAM; van Trotsenburg ASP; Kremer LCM; van Santen HM
Ann Nucl Med; 2022 Jun; 36(6):579-585. PubMed ID: 35499668
[TBL] [Abstract][Full Text] [Related]
12. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
14. Estimated Internal and External Radiation Exposure of Caregivers of Patients With Pediatric Neuroblastoma Undergoing 131I Metaiodobenzylguanidine Therapy: A Prospective Pilot Study.
Han S; Yoo SH; Koh KN; Lee JJ
Clin Nucl Med; 2017 Apr; 42(4):271-274. PubMed ID: 28098666
[TBL] [Abstract][Full Text] [Related]
15. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.
Picco P; Garaventa A; Claudiani F; Gattorno M; De Bernardi B; Borrone C
Cancer; 1995 Nov; 76(9):1662-4. PubMed ID: 8635072
[TBL] [Abstract][Full Text] [Related]
16. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
[TBL] [Abstract][Full Text] [Related]
17. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
[TBL] [Abstract][Full Text] [Related]
19. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
[TBL] [Abstract][Full Text] [Related]
20. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
